The US Food and Drug Administration has cleared a first-of-its-kind clinical trial for a next-generation cell therapy targeting several severe autoimmune diseases. The investigational therapy, CLBR001 + SWI019, is a switchable CAR-T (sCAR-T) treatment designed to eliminate the need for harsh pre-treatment chemotherapy, potentially offering a safer and more accessible path to a curative immune reset for patients.
The phase 1 trial will soon begin recruiting patients with myositis, systemic sclerosis, lupus, and rheumatoid arthritis. These conditions, part of a family of illnesses affecting up to 15 million people in the U.S., are often managed with lifelong immunosuppressants. While conventional CAR-T therapy has shown remarkable, potentially curative results in some autoimmune patients by reprogramming the immune system, it requires a toxic preparatory step called lymphodepletion. This chemotherapy wipes out a patient's existing immune cells to make room for the engineered CAR-T cells, increasing risks of infection and severe side effects.
The CLBR001 + SWI019 system aims to circumvent this major hurdle. It consists of two parts: the sCAR-T cells (CLBR001) and a protein-based "switch" (SWI019). This design allows doctors to precisely control the therapy's activity. Early data from oncology trials and preclinical autoimmune models suggest this approach can work without lymphodepletion, significantly reducing patient burden and treatment risk. Furthermore, in early cancer trials, the therapy demonstrated an ability to shorten the duration of serious side effects like cytokine release syndrome and showed robust expansion and persistence of the engineered cells.
Patient enrollment for the clinical trial is expected to commence shortly. If the trial successfully establishes the safety and efficacy of this switchable platform, it could transform the treatment paradigm for autoimmune diseases, moving from chronic suppression toward a more manageable, one-time curative strategy. Researchers are hopeful that success in these initial conditions could pave the way for the therapy's use across a much broader range of autoimmune disorders.